drugset / Trial / NCT00874744

Comparison of Single Intravitreal Injection of Triamcinolone or Bevacizumab for the Treatment of Diabetic Macular Edema

NCT00874744

Phase 2 Completed 13 enrolled Federal University of Goiás
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to compare a single intravitreal injection of 4.0 mg of triamcinolone acetonide and 1.25 mg of bevacizumab for the treatment of diabetic macular edema.

Timeline

Start
2008-03
Primary completion
2008-09
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 1.25 mg Intravitreal
Subject Triamcinolone Acetonide Other / unclassified 4 mg Intravitreal